Search
Pentoxyverine
go.drugbank.com/drugs/DB11186ApprovedWithdrawnIt is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists [A32160]. … Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties.
Mixtures: Pancold AProducts: PENTOXYVERIN AL 19MG/ML, PENTOXYVERIN AL 1.35 MG/MLBenzyl alcohol
go.drugbank.com/drugs/DB06770ApprovedInvestigationalMixtures: Fast Freeze Lidocaine Roll-OnCorifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalCorifollitropin alfa, also known as _Elonva_ is used in women undergoing fertility treatment to stimulate the development of more than one mature egg (oocyte) at a time in the ovaries. … This drug used together with _a gonadotropin-releasing hormone (GnRH) antagonist_, a type of medicine also used in fertility treatments. Elonva is available only by prescription [L2270].
Vorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalIt is the first in a new class of agents known as histone deacetylase inhibitors. … A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier
Remdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigational[A222398] Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola. … [A222393] Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017,[A191382] leading to considerable interest in remdesivir as a possible treatment for COVID-19.
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … The drug is only effective in patients with a susceptible IDH1 mutation.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexCerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigationalCerliponase alfa is a hydrolytic lysosomal N-terminal tripeptidyl peptidase-1 (TPP1). … [L51329] CLN2 is a predominantly pediatric-onset neurodegenerative disease caused by a deficiency in the lysosomal enzyme TPP1, leading to progressive impairment in motor and cognitive function.
Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl PeptidaseAbiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigationalAbiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis … [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.
Products: Abirateron 1A Pharma 500 mg - Filmtabletten, Abirateron 1A Pharma 1000 mg – FilmtablettenZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalZiconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds. … [A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.
Categories: Compounds used in a research, industrial, or household setting, Calcium Channels, N-Type